All In Biotech

Free tool

FAERS Monitor: Priftin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021024 or its brand name (Priftin, Rifapentine). Reports on generic versions are filed under their own applications.

Reports

526

Serious

379

72% of reports

Hospitalization

168

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug interaction67
  • pyrexia66
  • nausea52
  • fatigue48
  • vomiting44
  • hypertension40
  • off label use40
  • headache32
  • rash32
  • dizziness31
  • dyspnoea31
  • influenza like illness27
  • chills23
  • hypotension23
  • myalgia23

Reports by year received

View as table
YearReports
20073
20101
20111
20128
201315
201416
201520
201610
201773
201860
201950
202019
202158
202229
202313
202432
202573
202645

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,633 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug interactionSignal6716.913.5993
influenza like illnessSignal2713.19.1291
chillsSignal237.85.3131
pyrexiaSignal667.66.1380
hypertensionSignal407.65.6223
myalgiaSignal235.43.679
hypotensionSignal234.63.162
vomitingSignal443.72.888
rashSignal322.92.140
nauseaSignal522.62.053
dizzinessSignal312.51.827
fatigueSignal482.51.942
dyspnoeaSignal312.21.619
headacheSignal322.01.516
off label use401.81.415

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.